{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:34:09Z","timestamp":1790102049507,"version":"4.0.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>The study aimed to determine the incidence of adverse drug reactions (ADRs) among newly diagnosed tuberculosis (TB) patients receiving daily drug regimen with fixed-dose combination treatment under the National Tuberculosis Elimination Program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A community-based prospective cohort study was carried out in the Udupi district. Over 12 months, all newly diagnosed TB patients of either gender were included from 63 primary health centers and 6 community health centers, and ADRs were recorded by personal interviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 710 patients were enrolled, among whom 453 (63.8%), were males, and 257 (36.2%) were females. Pulmonary TB was diagnosed among 510 (71.8%) and 200 (28.2%) were extrapulmonary cases. During the intensive phase (IP) of treatment, 480 (67.6%) patients reported at least one ADR and 79 (11.1%) experienced two ADRs during IP and 31 (6.5%) had ADRs during the continuation phase. Out of 480, 140 (29.2%) had gastritis, 132 (27.5%) had vomiting, 105 (21.9%) had nausea, 60 (12.5%) had skin rashes, 27 (5.6%) had drug-induced hepatitis, and 16 (3.3%) had vision problems. Among 480 patients with ADRs, 462 (96.3%) had successful treatment outcomes, the remaining 17 patients (3.5%) died, and one (0.2%) had treatment failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Adverse events were more common in the 1\n                      <jats:sup>st<\/jats:sup>\n                      few months of treatment than in subsequent months. All mild-to-moderate ADRs were effectively managed, and most had successful treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/picr.picr_20_24","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T09:48:04Z","timestamp":1723196884000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Incidence of adverse drug reactions among tuberculosis patients initiated on daily drug regimen in a southern district of Karnataka"],"prefix":"10.4103","volume":"16","author":[{"given":"R. N. Hithaish","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Community Medicine, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chythra R.","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Maradi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashikiran","family":"Umakanth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. V. Chidananda","family":"Sanju","sequence":"additional","affiliation":[{"name":"District Tuberculosis Control Officer, District Tuberculosis Office, Udupi, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. S.","family":"Balu","sequence":"additional","affiliation":[{"name":"Centre for Digital Health, Artificial Intelligence, Research and Training, Basaweshwara Medical College and Hospital, Chitradurga, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"R4-20241226","doi-asserted-by":"crossref","first-page":"701","DOI":"10.13005\/bpj\/2173","article-title":"Adverse drug reactions monitoring in patients on antitubercular treatment in tertiary care hospital, Mandya","volume":"14","author":"Kiran","year":"2021","journal-title":"Biomed Pharm J"},{"key":"R5-20241226","first-page":"976","article-title":"Adverse drug reaction monitoring of antitubercular drugs during intensive phase at tertiary care medical college Hospital:A prospective study","volume":"10","author":"Ramakrishnan","year":"2020","journal-title":"Natl J Physiol Pharm Pharm"},{"key":"R6-20241226","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s15010-019-01324-3","article-title":"Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco","volume":"48","author":"El-Hamdouni","year":"2020","journal-title":"Infection"},{"key":"R7-20241226","doi-asserted-by":"crossref","first-page":"e65037","DOI":"10.1371\/journal.pone.0065037","article-title":"Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients:A prospective study","volume":"8","author":"Lv","year":"2013","journal-title":"PLoS One"},{"key":"R8-20241226","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4103\/2320-8775.123213","article-title":"Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy:Experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India","volume":"1","author":"Sinha","year":"2013","journal-title":"J Assoc Chest Physicians"},{"key":"R9-20241226","first-page":"e51418","article-title":"Tuberculosis and the Effectiveness of the Revised National Tuberculosis Control Program (RNTCP) to Control Tuberculosis:A Narrative Review","volume":"15","author":"Malwe","year":"2023","journal-title":"Cureus"},{"key":"R10-20241226","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ijtb.2020.01.003","article-title":"Have we missed reporting adverse drug reactions under revised national TB control programme?\u2013A mixed method study in Bengaluru, India","volume":"67","author":"Krishnappa","year":"2020","journal-title":"Indian J Tuberc"},{"key":"R11-20241226","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions:Definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"R12-20241226","first-page":"2229","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig","year":"1992","journal-title":"Am J Hosp Pharm"},{"key":"R13-20241226","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijtb.2019.02.005","article-title":"The end TB strategy for India","volume":"66","author":"Sachdeva","year":"2019","journal-title":"Indian J Tuberc"},{"key":"R14-20241226","doi-asserted-by":"crossref","first-page":"883483","DOI":"10.3389\/fphar.2022.883483","article-title":"Frequency and management of adverse drug reactions among drug-resistant tuberculosis patients:Analysis from a prospective study","volume":"13","author":"Massud","year":"2022","journal-title":"Front Pharmacol"},{"key":"R15-20241226","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1097\/MJT.0000000000000421","article-title":"Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients","volume":"25","author":"Ahmad","year":"2018","journal-title":"Am J Ther"},{"key":"R16-20241226","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4236\/jtr.2021.92008","article-title":"Prevalence of adverse drug reactions to econd line anti tuberculosis drugs in Nigeria:A cross-sectional study","volume":"9","author":"Ganiyu","year":"2021","journal-title":"J Tuberc Res"},{"key":"R17-20241226","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4103\/ijmy.ijmy_75_20","article-title":"Adverse drug reactions of anti-tuberculosis treatment among children with tuberculosis","volume":"9","author":"Laghari","year":"2020","journal-title":"Int J Mycobacteriol"},{"key":"R18-20241226","first-page":"66","article-title":"Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil:A prospective cohort study","volume":"2","author":"Araujo-Pereira","year":"2022","journal-title":"Front Trop Dis"},{"key":"R19-20241226","doi-asserted-by":"crossref","first-page":"7273935","DOI":"10.1155\/2016\/7273935","article-title":"Effect of Diabetes Mellitus on Tuberculosis Treatment Outcome and Adverse Reactions in Patients Receiving Directly Observed Treatment Strategy in India:A Prospective Study","volume":"2016","author":"Siddiqui","year":"2016","journal-title":"Biomed Res Int"},{"key":"R20-20241226","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ijtb.2021.07.010","article-title":"Evaluation of patient's experiences with daily DOTS","volume":"69","author":"Moorthy","year":"2022","journal-title":"Indian J Tuberc"}],"container-title":["Perspectives in Clinical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_20_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:01:07Z","timestamp":1787839267000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/picr.picr_20_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/picr.picr_20_24","relation":{},"ISSN":["2229-3485","2229-5488"],"issn-type":[{"value":"2229-3485","type":"print"},{"value":"2229-5488","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"2024-01-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}